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ABSTRACT
Background Alteplase improves functional outcomes of 
patients with acute ischaemic stroke, but its effects on 
symptomatic infarct swelling, an adverse complication 
of stroke and the influence of CT hyperdense artery sign 
(HAS) are unclear. This substudy of the Third International 
Stroke Trial aimed to investigate the association between 
HAS and symptomatic infarct swelling and effect of 
intravenous alteplase on this association.
Methods We included stroke patients whose 
prerandomisation scan was non- contrast CT. Raters, 
masked to clinical information, assessed baseline 
(prerandomisation) and follow- up (24–48 hours 
postrandomisation) CT scans for HAS, defined as an 
intracranial artery appearing denser than contralateral 
arteries. Symptomatic infarct swelling was defined as 
clinically significant neurological deterioration ≤7 days 
after stroke with radiological evidence of midline shift, 
effacement of basal cisterns or uncal herniation.
Results Among 2961 patients, HAS presence at baseline 
was associated with higher risk of symptomatic infarct 
swelling (OR 2.21; 95% CI 1.42 to 3.44). Alteplase 
increased the risk of swelling (OR 1.69; 95% CI 1.11 
to 2.57), with no difference between patients with and 
those without baseline HAS (p=0.49). In patients with 
baseline HAS, alteplase reduced the proportion with 
HAS at follow- up (OR 0.67; 95% CI 0.50 to 0.91), where 
HAS disappearance was associated with reduced risk of 
swelling (OR 0.25, 95% CI 0.14 to 0.47).
Conclusion Although alteplase was associated with 
increased risk of symptomatic infarct swelling in patients 
with or without baseline HAS, it was also associated with 
accelerated clearance of HAS, which in return reduced 
swelling, providing further mechanistic insights to underpin 
the benefits of alteplase.
INTRODUCTION
Symptomatic infarct swelling is a devas-
tating neurological complication of acute 
ischaemic stroke.1 Currently, there is insuffi-
cient evidence to inform its prevention and 
management in practice,2 although obser-
vational studies have shown that persistent 
arterial occlusion was associated with more 
infarct swelling and reperfusion appeared to 
reduce the risk of swelling.3 The hyperdense 
artery sign (HAS) on non- contrast CT is a 
widely accessible imaging sign in stroke prac-
tice,4 5 which is highly specific and moderately 
sensitive for detection of intracranial arterial 
obstruction by thrombus.6 However, the rela-
tionship between HAS and swelling is less 
clear as divergent findings were reported in 
previous studies.7–12
Although there are concerns that reper-
fusion therapies might increase infarct 
swelling, the Multicentre Randomised Clin-
ical Trial of Endovascular Treatment for 
Acute Ischaemic Stroke in the Netherlands 
(MR CLEAN) showed that successful reperfu-
sion by mechanical clot retrieval reduced the 
development of midline shift.13 Nevertheless, 
the impact of arterial recanalisation by intra-
venous thrombolysis on the development of 
severe infarct swelling is unknown.14 In the 
Third International Stroke Trial (IST-3), intra-
venous alteplase increased HAS clearance, 
and the disappearance of HAS was associated 
with better functional outcome.15 There-
fore, intravenous thrombolysis is a promising 
therapy for patients with HAS, particularly 
where thrombectomy is not available.
In this study, we used data from IST-3 to 
investigate whether the presence of HAS on 
baseline CT predicted development of symp-
tomatic infarct swelling and the effect of intra-
venous alteplase on this association.
METHODS
Third International Stroke Trial
IST-3 was an international, multicentre, 
prospective, randomised, open- blinded 
endpoint trial in acute ischaemic stroke 
comparing intravenous alteplase versus 
control, recruiting between May 2000 and July 
2011. IST-3 is registered, ISRCTN25765518. 
The detailed study design and methods of the 
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IST-3 have been described elsewhere.16–19 Briefly, patients 
were eligible if they had clinically definite acute stroke 
of any severity (assessed prior to randomisation with the 
National Institute of Health Stroke Scale (NIHSS)), age 
≥18 years, for whom CT or MRI had excluded intracra-
nial haemorrhage and any structural stroke mimics, and 
the treatment could be started within 6 hours of stroke 
onset, without clear indications for, or contraindications 
to, intravenous thrombolysis with alteplase. In total, 3035 
patients were randomised to receive standard care plus 
intravenous alteplase (0.9 mg/kg) or standard care alone. 
No intra- arterial therapy was used. Primary outcome was 
the functional status at 6 months assessed with the Oxford 
Handicap Scale. Results were analysed on an intention- to- 
treat basis. Collaborators and funders of IST-3 are listed 
in the online supplemental material 1.
Imaging protocol and analysis
The IST-3 imaging protocol has been described previ-
ously.16 20 All patients had a brain CT or MRI scan before 
randomisation and a follow- up scan at 24–48 hours after 
randomisation. A repeat brain scan was required if the 
patient deteriorated neurologically or intracranial haem-
orrhage was suspected for any reason. Non- contrast CT 
scans were required to cover the brain from foramen 
magnum to vertex, with maximum slice thickness of 
4–5 mm through the posterior fossa and 8–10 mm for 
the cerebral hemispheres, with no slice gap. Scans were 
windowed on 80 Hounsfield Units (HU) width and 
centre level of 35–40 HU. A centralised panel of neurol-
ogists and neuroradiologists experienced in acute stroke 
imaging evaluated all relevant CT scans using a validated, 
prespecified rating proforma ( www. ed. ac. uk/ clinical- 
sciences/ edinburgh- imaging/ research/ analysis- and- 
processing/ image- analysis- tools- downloads/ all- the- edin-
burgh- imaging- rating- tools).5 16 21 All raters were blinded 
to clinical data and imaging at other time points.
HAS presence was determined visually on non- contrast 
CT on both baseline (prerandomisation) and follow- up 
(24–48 hour postrandomisation) scans. No objective HU 
measurements were made, as in prior research, we found 
that this approach did not materially increase sensitivity 
or specificity for acute thrombus.22 23 The raters identified 
HAS by deciding if an intracranial artery appeared denser 
than adjacent arteries or than equivalent contralateral 
arteries, but not due to calcification, at the following 
locations: internal carotid artery, mainstem or sylvian 
branches of middle cerebral artery (MCA), anterior cere-
bral artery (ACA), posterior cerebral artery (PCA), verte-
bral or basilar arteries. In a large observer reliability study 
based on the IST-3 imaging data, the inter- rater and intra- 
rater reliability of HAS identification by Krippendorff α 
was 0.59 and 0.58, respectively.6 The status of HAS was 
recorded as ‘persistent’ for HAS present on both base-
line and follow- up CT; ‘disappeared’ for HAS present at 
baseline but not follow- up; ‘newly developed’ for HAS not 
present on baseline CT but on follow- up CT’ and ‘none’ 
for HAS absent at both baseline and follow- up.
We assessed the extent of the acute ischaemic lesion 
using the IST-3 score, which includes all arterial territo-
ries and differentiates infarct extent from brain swelling.16 
The score has been widely validated and shown to have 
better inter- rater reliability and dynamic range than other 
infarct extent scores.16 21 24 We condensed the full- lesion 
extent scores into four groups for analysis, as previously16: 
small infarcts, defined as lacunar, small cortical, small 
cerebellar, less than half of brainstem or less than half 
of the ACA or PCA territory; medium infarcts, defined 
as striatocapsular, the anterior or posterior half of the 
peripheral MCA territory or more than half of the ACA 
or PCA territory; large infarcts, defined as the whole of 
the peripheral MCA territory or all the MCA territory and 
very large infarcts, defined as the whole MCA and PCA 
territory, the whole MCA and ACA territory or all three 
territories.
Definition of symptomatic infarct swelling
The outcome in this analysis was prespecified in the IST-3 
study protocol,17 19 where symptomatic infarct swelling 
was defined as clinically significant neurological deteri-
oration (as assessed and reported by trial investigators 
according to their local protocol) or death ≤7 days of 
randomisation, accompanied by evidence of signifi-
cant infarct swelling as determined by the independent 
masked expert assessment of the scan. Significant infarct 
swelling was defined as any degree of the shift of the 
midline cerebral structures away from their usual central 
location in the brain, effacement of the basal cisterns or 
uncal herniation on a follow- up scan or finding severe 
infarct swelling at autopsy if not rescanned before death. 
The presence of some degree of haemorrhagic transfor-
mation was permitted, provided it was not considered by 
the expert imaging rater to be a major contributor to the 
mass effect.
Statistical analysis
Patients whose prerandomisation radiological assessment 
was a non- contrast CT scan that had undergone blinded 
central review were included in this analysis. We excluded 
the few patients with prerandomisation MRI scans. We 
compared clinical characteristics between patients with 
and without symptomatic infarct swelling, using t- tests, 
Wilcoxon test or χ2 tests as appropriate. We performed 
tests of interaction to compare ORs for the association 
between HAS and symptomatic infarct swelling in patients 
with an initial NIHSS <15 versus ≥15; patients with large 
to very large infarcts versus small to medium infarcts and 
patients allocated to alteplase versus those on control. 
We also used logistic regression with symptomatic infarct 
swelling as dependent variable to calculate ORs for HAS, 
adjusted for the effects of patient age, NIHSS, extent of 
ischaemic lesion and allocation to alteplase. IST-3 was 
powered to detect the clinical difference in the primary 
outcome, and the clinical (symptomatic infarct swelling) 
and imaging (HAS) variables for secondary analysis were 
prespecified.17 18 20 In addition, we had been cautious 
 on D
ecem














 3Wu S, et al. Stroke & Vascular Neurology 2020;0. doi:10.1136/svn-2020-000569
Open access
with the number of variables allowed in regression anal-
ysis to satisfy the sample size criterion of ≥10 events per 
variable.25 26 Therefore, the study was anticipated to 
be sufficient to enable the assessment of the effects of 
alteplase on HAS and on infarct swelling. All analyses 
were performed with SAS software V.9.4 (SAS Institute, 
Cary, North Carolina, USA). All tests were two sided with 
p<0.05 as significant.
RESULTS
Of 3035 patients randomised in the IST-3, non- contrast 
CT scans were centrally reviewed for 2961 patients at 
baseline (18/3035 patients with baseline CT were not 
available for central review and MRI only was performed 
at baseline in the remaining 56/3035 patients) and for 
2731 patients at both baseline and follow- up. HAS data 
were missing for one follow- up CT due to poor quality 
scan, thus 2730 patients had HAS data at both baseline 
and follow- up.
Associations between baseline HAS and symptomatic infarct 
swelling
Of 2961 patients with baseline CT scans (mean age, 77.4 
(SD, 12.1) years; men, 48.2%; onset to scan time, median 
3 (IQR, 2–4 hours), 716 (24.2%)) demonstrated base-
line HAS and 107 (3.6%) developed symptomatic infarct 
swelling ≤7 days after stroke onset (median, 3 (IQR 1–4) 
days). Patients with baseline HAS had higher NIHSS 
(median, 16 (IQR 10–20]) than those without HAS 
(median, 9 (IQR 6–16); p<0.001). Patients were more 
likely to develop symptomatic infarct swelling if they 
had baseline HAS (unadjusted OR, 4.83 (95% CI 3.25 to 
7.16); p<0.001), NIHSS ≥15 (unadjusted OR, 8.82 (95% 
CI 5.34 to 14.56); p<0.001), large to very large infarcts 
(unadjusted OR, 5.76 (95% CI 3.89 to 8.52); p<0.001) and 
were allocated to alteplase (unadjusted OR, 1.70 (95% CI 
1.14 to 2.53); p=0.008). There was no association between 
symptomatic infarct swelling and age, sex or time from 
onset to randomisation (table 1). The sensitivity and spec-
ificity of baseline HAS for predicting symptomatic infarct 
swelling was 0.59 (95% CI 0.50 to 0.64) and 0.77 (95% CI 
0.73 to 0.82), respectively. Baseline HAS was associated 
with a higher risk of death ≤7 days (unadjusted OR, 2.16 
(95% CI 1.66 to 2.82); p<0.001), and the development of 
symptomatic infarct swelling did not change the adverse 
association of baseline HAS with early death (p for inter-
action 0.11).
In multivariable analysis, the risk of symptomatic infarct 
swelling increased independently with higher NIHSS, 
larger infarcts, presence of baseline HAS and allocation 
to alteplase and decreased with increasing age (table 2). 
The association between HAS and symptomatic infarct 
Table 1 Baseline characteristics and 7 day fatality of patients with and without symptomatic infarct swelling
Symptomatic infarct 
swelling (n=107)
No symptomatic infarct 
swelling (n=2854) P values
Age, years, mean (SD) 76.8 (12.5) 77.4 (12.1) 0.59
Sex, n (%)* 0.76
  Male 50 (3.5) 1377 (96.5)
  Female 57 (3.7) 1477 (96.3)
Baseline NIHSS, median (IQR) 19 (17–23) 11 (6–17) <0.001
NIHSS, n (%)* <0.001
  NIHSS ≥15 88 (8.2) 983 (91.8)
  NIHSS <15 19 (1.0) 1871 (99.0)
Infarct size on pre- randomisation CT, n (%)* <0.001
  Large/very large 55 (11.0) 443 (89.0)
  None/small/medium 52 (2.1) 2411 (97.9)
Hyperdense artery sign on prerandomisation CT, n (%)* <0.001
  HAS 63 (8.8) 653 (91.2)
  No HAS 44 (2.0) 2201 (98.0)
Allocated treatment, n (%)* 0.008
  Alteplase 67 (4.5) 1417 (95.5)
  Control 40 (2.7) 1437 (97.3)
Death in first 7 days, n (%)† 70 (65.4) 192 (6.7) <0.001
Time from onset to randomisation, hours, median 
(IQR)
3.5 (2.7–4.2) 3.9 (2.9–4.9) 0.14
*The proportion of patients with/without infarct swelling in each row characteristic subgroup.
†The proportion of patients who died ≤7 days in patients with/without symptomatic infarct swelling.
HAS, hyperdense artery sign; NIHSS, National Institute of Health Stroke Scale.
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swelling was stronger among patients with baseline 
NIHSS <15 than those with NIHSS ≥15 (OR, 7.44 (95% 
CI 2.97 to 18.64) vs OR, 2.49 (95% CI 1.60 to 3.88); p for 
interaction 0.04), but this interaction between HAS and 
NIHSS was no longer present when a linear function of 
NIHSS was assessed in multivariable regression, adjusted 
for age, baseline HAS, large to very large infarct and allo-
cation to alteplase (p=0.37, data not shown). The effects 
of alteplase (p for interaction 0.49) and of large to very 
large infarcts (p for interaction 0.81) on increased risk of 
symptomatic infarct swelling showed no significant inter-
action with baseline HAS presence or absence.
Effect of alteplase on the development of symptomatic infarct 
swelling
Of 2730 patients with information on HAS on both base-
line and follow- up CT, HAS was identified on 673 (24.7%) 
baseline scans, of whom 60 (8.9% of 673) patients devel-
oped symptomatic infarct swelling. Alteplase increased 
the risk of symptomatic infarct swelling in general, and 
this pattern persisted regardless of changes in HAS 
(table 3).
Of 673 patients with baseline HAS, alteplase reduced 
persistent HAS (152/350, 43.4%, allocated alteplase vs 
172/323, 53.3%, allocated control; unadjusted OR, 0.67 
(95% CI 0.50 to 0.91); p=0.01). Patients with higher 
NIHSS (median, 17 (IQR 13–21) vs median, 14 (IQR 
9–19); p<0.001) and large to very large infarcts (152/272, 
55.9% vs 172/401, 42.9%; p<0.001) were more likely to 
have persistent HAS. Patients whose HAS disappeared 
were less likely to develop symptomatic infarct swelling 
than those with persistent HAS on follow- up (14/349, 
4.0%, disappeared HAS vs 46/324, 14.2%, persistent HAS; 
unadjusted OR, 0.25 (95% CI 0.14 to 0.47); p<0.001).
Of 2057 patients without baseline HAS, there were 
fewer newly developed HAS in the alteplase group 
(90/1047, 8.6%) than the control group (106/1010, 
10.5%), although the difference was not statistically 
significant (unadjusted OR, 0.80 (95% CI 0.60 to 1.09); 
p=0.16). Patients with newly developed HAS (n=196) on 
follow- up CT were more likely to develop infarct swelling 
than the remaining 1861 patients (unadjusted OR, 4.19 
(95% CI 2.16 to 8.16); p<0.001).
DISCUSSION
In this IST-3 cohort of 2961 patients with baseline CT, the 
presence of HAS, either on baseline CT, or persisting or 
newly developed on follow- up CT, was associated with a 
higher risk of developing symptomatic infarct swelling ≤7 
days after stroke. Alteplase increased the risk of developing 
infarct swelling at follow- up whether or not HAS was present 
at baseline. However, at follow- up, alteplase promoted HAS 
disappearance in patients with baseline HAS and reduced 
development of new HAS in those without baseline HAS, 
and these patients then had less risk of infarct swelling. These 
findings provide further evidence of benefits of alteplase in 
not only removing thrombus but also reducing secondary 
Table 2 Multivariable logistic regression for symptomatic infarct swelling
Factors Beta OR 95% CI P values
Age* −0.02 0.98 0.97 to 0.99 0.04
NIHSS* 0.14 1.15 1.11 to 1.18 <0.001
Large to very large infarct (vs small to medium infarct) 0.89 2.44 1.57 to 3.79 <0.001
Allocated alteplase (vs control) 0.53 1.69 1.11 to 2.57 0.01
HAS presence (vs absence) 0.79 2.21 1.42 to 3.44 <0.001
*Entered as linear variables, where the OR reflected the expected change in odds for one- point increase in NIHSS or 1- year increase in age.
HAS, hyperdense artery sign; NIHSS, National Institute of Health Stroke Scale.
Table 3 Effect of alteplase on the development of symptomatic infarct swelling by change in HAS between baseline and 
follow- up
Baseline HAS
Changes in HAS at follow- 
up Alteplase n/N* Control n/N*
Effect of alteplase on development 
of infarct swelling, OR (95% CI)




Persistent (n=324) 28/152 18/172 1.93 (1.02 to 3.66) 0.62; d.f.=1
Disappeared (n=349) 9/198 5/151 1.39 (0.46 to 4.24)
Subtotal 37/350 23/323 1.54 (0.89 to 2.66)
Absence
(n=2057)
Newly developed (n=196) 8/90 5/106 1.97 (0.62 to 6.25) 0.98; d.f.=1
None (n=1861) 21/957 10/904 2.01 (0.94 to 4.28)
Subtotal 29/1047 15/1010 1.89 (1.01 to 3.55)
Total NA 66/1397 38/1333 1.69 (1.13 to 2.54) 0.96; d.f.=3
*N or n=number of patients in each subgroup of morphological changes in HAS presence, n/N: n=number of patients with infarct 
swelling.
d.f., degree of freedom; HAS, hyperdense artery sign; NA, not applicable.
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adverse effects of stroke, thereby altering the natural history 
of ischaemic lesion progression towards a better chance of 
recovery. Alteplase became a World Health Organisation 
Essential Medicine in 2018. It is widely used over the world 
in patients with acute ischaemic stroke and is available for 
patients who do not meet criteria for thrombectomy, where 
thrombectomy is unavailable, and as adjunct therapy to 
thrombectomy. Therefore, these results are relevant to a 
large proportion of patients with acute ischaemic stroke.
Previous studies reported that HAS at baseline was associ-
ated with infarct swelling in patients with stroke treated with 
alteplase.27 28 We have clarified that HAS increases symp-
tomatic infarct swelling in both patients allocated alteplase 
and those allocated control, and separately, that alteplase 
increases symptomatic infarct swelling regardless of the 
presence or absence of baseline HAS. In this large cohort, 
baseline HAS showed moderate sensitivity and specificity 
for development of symptomatic infarct swelling, indicating 
that HAS is just one of several predictors that contributes to 
swelling. The presence of HAS is associated with more severe 
stroke and larger infarct size,29 30 where the latter two also 
predict symptomatic infarct swelling.3 31 We further show that 
HAS increases symptomatic infarct swelling independent of 
NIHSS and infarct size. Our results also suggest that HAS in 
patients with NIHSS <15 may be a useful warning of increased 
risk of symptomatic infarct swelling, that is, in patients who 
may otherwise not be expected to develop this complication, 
but this requires further testing. In addition, we confirm that 
older patients are less likely to develop symptomatic infarct 
swelling independent of HAS, NIHSS, large infarct size and 
alteplase, possibly attributable to the buffering space for 
swelling provided by the age- related brain atrophy.
Although alteplase promoted HAS disappearance and 
improved functional outcome,17 we show that it increases 
symptomatic infarct swelling in general, independent of 
HAS presence. However, in patients with baseline HAS, 
who therefore have a high risk of symptomatic infarct 
swelling, alteplase promoted HAS disappearance and 
thus reduced symptomatic infarct swelling. Therefore, 
it appears that the increased risk of symptomatic infarct 
swelling by alteplase was outweighed by the benefit that 
resulted from its ability to accelerate racanalisation in this 
patient group with baseline HAS. Despite this benefit, 
some patients with baseline HAS allocated to alteplase 
had the persistent risk of swelling, which may be partly 
due to unsuccessful reperfusion. Similar findings were 
reported in the MR CLEAN trial, where successful reca-
nalisation but not the allocation to endovascular treat-
ment was associated with a lower risk of midline shift on 
follow- up scans.13 Although thrombectomy may provide 
a higher proportion of recanalisation and some patients 
in IST-3 described in the present analysis would now be 
candidates for thrombectomy, intravenous alteplase is 
more accessible than thrombectomy for stroke patients 
in many areas and should not be withheld from patients 
presenting with HAS even where thrombectomy is being 
considered.32 Our findings from the IST-3, together 
with the benefit shown in the MR CLEAN trial, provide 
evidence that patients at risk of infarct swelling could 
benefit from reperfusion therapies, either by intravenous 
thrombolysis or mechanical clot retrieval.
Our study has some limitations. First, we assessed HAS 
qualitatively on non- contrast CT without HU measure-
ment, since the visual assessment of HAS is clinically 
relevant and highly specific for angiographic obstruction 
with good reliability across a wide range of raters,4–6 and 
that HU measurement does not improve sensitivity or 
specificity.22 23 Second, we did not verify the association 
between HAS and angiographic arterial obstruction for 
current analysis, because we do not have angiography 
for all of these patients and notwithstanding, we wish to 
focus on the imaging sign on non- contrast CT—a tech-
nique that is widely accessible and rapidly translatable in 
clinical practice, and since many patients, in many parts 
of the world, for many reasons, do not receive routine 
CT angiography. Therefore, our findings could translate 
immediately to the generality of stroke worldwide.
CONCLUSION
Patients with HAS on non- contrast CT ≤48 hours after 
stroke onset were more likely to develop symptomatic 
infarct swelling within 7 days after stroke. Overall, intra-
venous alteplase increased the risk of symptomatic infarct 
swelling, but this risk reduced in patients whose baseline 
HAS had disappeared at follow- up, likely mediated by 
removal of obstructing thrombus and improved tissue 
reperfusion, consistent with the clinical benefit of intra-
venous alteplase.
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